Why Promising Cancer Drugs Failed: Scientists Uncover the Missing Piece

A new study helps explain why a promising class of cancer drugs has often failed to meet expectations in clinical trials. For more than ten years, researchers have tested a group of cancer drugs known as BET inhibitors with high hopes. The science appeared solid. Many tumors rely on oncogenes that “Bromo- and Extra-Terminal domain” [...]